CIENBY Trademark

Trademark Overview


On Tuesday, April 30, 2024, a trademark application was filed for CIENBY with the United States Patent and Trademark Office. The USPTO has given the CIENBY trademark a serial number of 98527570. The federal status of this trademark filing is NON-FINAL ACTION - MAILED as of Monday, June 3, 2024. This trademark is owned by Fresenius Medical Care Holdings, Inc.. The CIENBY trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical solutions used in dialysis
cienby

General Information


Serial Number98527570
Word MarkCIENBY
Filing DateTuesday, April 30, 2024
Status641 - NON-FINAL ACTION - MAILED
Status DateMonday, June 3, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesPharmaceutical solutions used in dialysis

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, April 30, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameFresenius Medical Care Holdings, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressWaltham, MA 02451

Trademark Events


Event DateEvent Description
Tuesday, April 30, 2024NEW APPLICATION ENTERED
Tuesday, April 30, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sunday, June 2, 2024ASSIGNED TO EXAMINER
Monday, June 3, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, June 3, 2024NON-FINAL ACTION WRITTEN
Monday, June 3, 2024NON-FINAL ACTION E-MAILED